Administration of FGF21, FGF21 analogs or adenoviral delivery of FGF21 reduces hepatic steatosis in diverse rodent models of NAFLD and NASH (101, 126–129). Here, FGF21 is linked to metabolic dysfunction-associated steatotic liver disease.